Table 2 Diagnostic performance of baseline ctDNA detection compared to three clinical endpoints—residual cancer burden (RCB 0–2 vs. 3), ultrasound response (US responder vs. non‑responder) and cell‑cycle arrest (CCCA; Ki‑67 ≤ 2.7% vs. > 2.7%)—expressed as sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)

From: Personalized ctDNA detection and genomic profiling in the NeoRHEA Study